Protein binding of vancomycin in a patient with immunoglobulin A myeloma

Area of Science:

• Pharmacology
• Oncology
• Immunology

Background:

• Vancomycin is a critical antibiotic for treating serious Gram-positive bacterial infections.
• Immunoglobulin A (IgA) myeloma is a malignancy of plasma cells producing abnormal IgA.

Observation:

• A patient with IgA myeloma exhibited unusual vancomycin pharmacokinetics.
• The patient presented with extremely high serum vancomycin concentrations and a prolonged elimination half-life.
• Vancomycin treatment was ineffective in this patient, despite preserved renal function.

Findings:

• Atypical vancomycin pharmacokinetics were characterized by elevated drug levels and prolonged half-life.
• Extensive binding of vancomycin to an aberrant immunoglobulin A protein is hypothesized as the cause.
• Normal renal function did not prevent the observed pharmacokinetic alterations.

Implications:

• This case highlights the potential for aberrant proteins in myeloma to interfere with drug pharmacokinetics.
• Therapeutic drug monitoring and consideration of protein binding are crucial in patients with IgA myeloma receiving vancomycin.
• Further research is needed to understand and manage drug-protein interactions in hematologic malignancies.